Ask about this productRelated genes to: DPP4 antibody
- Gene:
- DPP4 NIH gene
- Name:
- dipeptidyl peptidase 4
- Previous symbol:
- CD26, ADCP2
- Synonyms:
- DPPIV
- Chromosome:
- 2q24.2
- Locus Type:
- gene with protein product
- Date approved:
- 1990-03-05
- Date modifiied:
- 2016-02-05
Related products to: DPP4 antibody
Related articles to: DPP4 antibody
- Radioactive iodine (RAI) resistance severely limits treatment efficacy in thyroid carcinoma (THCA), yet its molecular underpinnings remain incompletely elucidated. In the present study, we sought to reveal the molecular mechanism by which histone lysine methyltransferase 2B (KMT2B) regulated dipeptidyl peptidase 4 (DPP4)-mediated THCA resistance to RAI. - Source: PubMed
Publication date: 2026/04/21
Wang MeiqunWang ZhiYang HaifengZhou Tao - The effects of L. extract (HSE) as a supplemental therapy with valsartan for type 2 diabetic patients with nephropathy and its underlying biological functions were investigated in this study. - Source: PubMed
Kiani MaryamMirzaei HassanEnayati AyeshehGhorbani SomayehZengin GokhanAmirkhanlou Saeid - Type 2 diabetes mellitus (T2DM) remains a global health challenge characterized by insulin resistance and impaired incretin effects. This has spurred research into potential therapeutic agents from natural sources that can inhibit both protein tyrosine phosphatase 1B (PTP1B) and dipeptidyl peptidase 4 (DPP4), which are implicated in these diabetes effects. This study explored the therapeutic potential of , , and through a dual approach: in vitro enzyme inhibition assays of their essential oils and computational modeling of their broader characteristic phytochemicals. Experimental results identified essential oil as the most potent source, yielding IC values of 27.26 μg/ml for PTP1B and 42.28 μg/ml for DPP4. To explore the wider polypharmacological potential of these botanical sources beyond the volatile fraction, computational screening of the plant metabolites was done, which highlighted nonvolatile flavonoids quercetin-3,7-diglucoside (Q37DG) and quercetin-7-O-glucoside (Q7G) as primary theoretical leads of . MMGBSA analysis confirmed exceptional binding affinities for Q37DG (Δ of -52.19 kcal/mol for PTP1B and -58.23 kcal/mol for DPP4), driven by van der Waals interactions and engagement with critical catalytic residues (Glu, Asp, Glu, and Ser). DFT calculations established that molecular softness and LUMO energies are key descriptors of inhibitory reactivity. While genetic algorithm QSAR models ( > 0.88) validated the theoretical potency of these leads, pharmacokinetic profiling identified important translation bottlenecks, including low gastrointestinal absorption. Consequently, these flavonoids are characterized as early-stage pharmacological probes and structural templates for multi-target optimization. This is interdisciplinary research that identifies botanical polypharmacological leads for diabetes. - Source: PubMed
Publication date: 2026/04/16
Adedirin OluwaseyeSabiu Saheed - Diabetes mellitus represents a global health crisis requiring innovative therapeutic strategies beyond traditional treatments. This comprehensive review analyzes heterocyclic frameworks developed between 2020-2024 for antidiabetic drug discovery, highlighting structure-activity relationships (SAR), molecular docking insights, and therapeutic mechanisms. Key scaffold classes emerged as potent antidiabetic agents, with benzimidazoles and triazoles demonstrating dual α-amylase/α-glucosidase inhibition (IC values 1.20-22.46 µg/mL), thiazolidinediones and quinazolines showing PPAR-γ agonism with improved insulin sensitivity and reduced cardiovascular risks, DPP-4 inhibitory scaffolds (pyrrolidines, pyrimidines) achieving IC values as low as 0.021 µM, and SGLT2-targeting heterocycles exhibiting glucose-lowering effects with cardio-renal protection. Major findings revealed that electron-donating groups (methoxy, hydroxyl) consistently enhanced binding affinity across multiple targets, halogen substitutions (fluoro, chloro, bromo) improved metabolic stability and selectivity, hybrid molecules combining multiple pharmacophores achieved superior multi-target effects, and natural product-derived heterocycles (flavonoids, coumarins, alkaloids) showed ICvalues 10-100× better than acarbose. Emerging frontiers include multi-agonist therapies (GLP-1/GIP, dual SGLT1/SGLT2 inhibitors), glucokinase activators for insulin-independent glucose control, microbiome-targeting agents, and AI-driven rational drug design integrating SAR, docking, and ADMET prediction. This review provides a strategic framework for developing safer, more selective antidiabetic agents through systematic exploitation of heterocyclic chemistry, advancing toward personalized diabetes management. - Source: PubMed
Publication date: 2026/04/20
Tahlan SumitSingh SuchetaDey HrithikKaira MeenakshiPandey Kailash C - Over three decades ago, our group reported that newly diagnosed Black patients with DKA are obese and that many of them can discontinue insulin after the acute episode, revealing a clinical course consistent with type 2 diabetes. This presentation is now recognized as ketosis-prone type 2 diabetes mellitus (KPDM). - Source: PubMed
Publication date: 2026/04/17
Umpierrez GuillermoVellanki PriyathamaOladejo Omolade